<- Go Home
DNIB Unwind, Inc.
On October 11, 2016, DNIB Unwind, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. DNIB Unwind, Inc. engaged in the development of novel targeted therapeutics primarily for the treatment of cancer in the United States and Russia. The company was formerly known as BIND Therapeutics, Inc. and changed its name to DNIB Unwind, Inc. in August 2016. DNIB Unwind, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
Market Cap
$3.0M
Volume
215.3K
Cash and Equivalents
$7.0M
EBITDA
-$36.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$25.7M
Profit Margin
173.14%
52 Week High
$5.24
52 Week Low
$0.11
Dividend
N/A
Price / Book Value
-0.90
Price / Earnings
-0.08
Price / Tangible Book Value
-0.90
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$39.9M
Return on Equity
259.74%
Return on Assets
-54.84
Cash and Short Term Investments
$7.0M
Debt
$8.3M
Equity
-$3.4M
Revenue
$14.8M
Unlevered FCF
-$19.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium